Uno studio per indagare l'efficacia e la sicurezza di anifrolumab negli adulti con lupus eritematoso cutaneo cronico e/o subacuto (LAVENDER)
Uno studio di fase III multicentrico, randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia e la sicurezza di anifrolumab negli adulti con lupus eritematoso cutaneo cronico e/o subacuto refrattari e/o intolleranti alla terapia antimalarica
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Ciudad de Buenos Aires, Argentina, 1221
- Research Site
-
Córdoba, Argentina, 5000
- Research Site
-
Córdoba, Argentina, X5004BAL
- Research Site
-
Quilmes, Argentina, 1878
- Research Site
-
San Miguel, Argentina, 1663
- Research Site
-
-
-
-
-
Kogarah, Australia, 3168
- Research Site
-
Melbourne, Australia, 3004
- Research Site
-
Mitcham, Australia, 3132
- Research Site
-
Westmead, Australia, 2145
- Research Site
-
Woolloongabba, Australia, 04102
- Research Site
-
-
-
-
-
Graz, Austria, 8036
- Research Site
-
Innsbruck, Austria, 6020
- Research Site
-
Linz, Austria, 4020
- Research Site
-
Vienna, Austria, 1130
- Research Site
-
-
-
-
-
Belo Horizonte, Brasile, 30150-221
- Research Site
-
Porto Alegre, Brasile, 90035903
- Research Site
-
Rio de Janeiro, Brasile, 22470-220
- Research Site
-
Salvador, Brasile, 40150-150
- Research Site
-
São Paulo, Brasile, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulgaria, 1784
- Research Site
-
Sofia, Bulgaria, 1463
- Research Site
-
Sofia, Bulgaria, 1528
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Research Site
-
Toronto, Ontario, Canada, M5T 2S8
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Changchun, Cina, 130021
- Research Site
-
Changsha, Cina, 410011
- Research Site
-
Chengdu, Cina, 610021
- Research Site
-
Chongqing, Cina, 400016
- Research Site
-
Dongguan, Cina, 523059
- Research Site
-
Guangzhou, Cina, 510120
- Research Site
-
Heilongjiang, Cina, 150086
- Research Site
-
Jinan, Cina, 250022
- Research Site
-
Shanghai, Cina, 200025
- Research Site
-
Shanghai, Cina, 200443
- Research Site
-
Shenzhen, Cina, 518053
- Research Site
-
Shenzhen, Cina, 518020
- Research Site
-
Shenzhen, Cina, 518052
- Research Site
-
Zhuzhou, Cina, 412007
- Research Site
-
Ürümqi, Cina, CN-830004
- Research Site
-
-
-
-
-
Barranquilla, Colombia, 080020
- Research Site
-
Bogotá, Colombia, 110221
- Research Site
-
-
-
-
-
Seoul, Corea del Sud, 03080
- Research Site
-
Seoul, Corea del Sud, 06591
- Research Site
-
Seoul, Corea del Sud, 06973
- Research Site
-
-
-
-
-
Aarhus, Danimarca, 641-8510
- Research Site
-
Copenhagen, Danimarca, 2100
- Research Site
-
-
-
-
-
Iloilo City, Filippine, 5000
- Research Site
-
Lipa, Filippine, 4217
- Research Site
-
Manila, Filippine, 1000
- Research Site
-
-
-
-
-
Bois-Guillaume, Francia, 76031
- Research Site
-
Dijon, Francia, 21000
- Research Site
-
Lyon, Francia, 69437
- Research Site
-
Montivilliers, Francia, 76290
- Research Site
-
Nantes, Francia, 44000
- Research Site
-
Paris, Francia, 75010
- Research Site
-
Paris, Francia, 75014
- Research Site
-
Paris, Francia, 75013
- Research Site
-
Paris, Francia, 75970
- Research Site
-
Poitiers, Francia, 86000, FR
- Research Site
-
Toulouse, Francia, 31059
- Research Site
-
-
-
-
-
Berlin, Germania, 10117
- Research Site
-
Bochum, Germania, 44791
- Research Site
-
Dresden, Germania, 01307
- Research Site
-
Erlangen, Germania, 91054
- Research Site
-
Essen, Germania, 45147
- Research Site
-
Freiburg im Breisgau, Germania, 79104
- Research Site
-
Hanover, Germania, 30625
- Research Site
-
Kiel, Germania, 24105
- Research Site
-
Leipzig, Germania, 04103
- Research Site
-
Mainz, Germania, 55131
- Research Site
-
Marburg, Germania, 35043
- Research Site
-
Regensburg, Germania, 93053
- Research Site
-
Wuppertal, Germania, 42283
- Research Site
-
-
-
-
-
Chūōku, Giappone, 104-8560
- Research Site
-
Fukuoka, Giappone, 812-8582
- Research Site
-
Kanazawa, Giappone, 920-8641
- Research Site
-
Kita-gun, Giappone, 761-0793
- Research Site
-
Nagoya, Giappone, 457-8510
- Research Site
-
Nagoya, Giappone, 467-8602
- Research Site
-
Wakayama, Giappone, 641-8510
- Research Site
-
Yokohama, Giappone, 232-0024
- Research Site
-
tabashi City, Giappone, 173-8606
- Research Site
-
-
-
-
-
Athens, Grecia, 12462
- Research Site
-
Athens, Grecia, 16121
- Research Site
-
-
-
-
-
Brescia, Italia, 25123
- Research Site
-
Cona, Italia, 44124
- Research Site
-
Florence, Italia, 50121
- Research Site
-
Milan, Italia, 20132
- Research Site
-
Naples, Italia, 80138
- Research Site
-
Reggio Emilia, Italia, 42123
- Research Site
-
Roma, Italia, 00144
- Research Site
-
Rome, Italia, 00168
- Research Site
-
-
-
-
-
Guadalajara, Messico, 44340
- Research Site
-
Guadalajara, Messico, 44610
- Research Site
-
Mexico City, Messico, 07760
- Research Site
-
Veracruz, Messico, 91910
- Research Site
-
-
-
-
-
Papatoetoe, Nuova Zelanda, 2025
- Research Site
-
-
-
-
-
Breda, Olanda, 4818 CK
- Research Site
-
Rotterdam, Olanda, 3015 GD
- Research Site
-
-
-
-
-
Katowice, Polonia, 40-851
- Research Site
-
Kielce, Polonia, 25-316
- Research Site
-
Ossy, Polonia, 40-027
- Research Site
-
Rzeszów, Polonia, 35-055
- Research Site
-
Warsaw, Polonia, 02-637
- Research Site
-
-
-
-
-
Braga, Portogallo, 4710-243
- Research Site
-
Lisbon, Portogallo, 1649-035
- Research Site
-
Porto, Portogallo, 4099-001
- Research Site
-
-
-
-
-
Cambridge, Regno Unito, CB2 0QQ
- Research Site
-
Leeds, Regno Unito, LS2 9JT
- Research Site
-
London, Regno Unito, NW1 2PG
- Research Site
-
London, Regno Unito, SE5 9RS
- Research Site
-
London, Regno Unito, SE1 7EH
- Research Site
-
London, Regno Unito, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Regno Unito, NE1 4LP
- Research Site
-
-
-
-
-
Bucharest, Romania, 020125
- Research Site
-
Iași, Romania, 700291
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Research Site
-
Kragujevac, Serbia, 34000
- Research Site
-
-
-
-
-
Košice, Slovacchia, 04001
- Research Site
-
Piešťany, Slovacchia, 92101
- Research Site
-
-
-
-
-
Barcelona, Spagna, 8035
- Research Site
-
Barcelona, Spagna, 08025
- Research Site
-
Castellon, Spagna, 12004
- Research Site
-
Granada, Spagna, 18012
- Research Site
-
L'Hospitalet de Llobregat, Spagna, 08907
- Research Site
-
Las Palmas de Gran Canaria, Spagna, 35010
- Research Site
-
Madrid, Spagna, 28034
- Research Site
-
Madrid, Spagna, 28041
- Research Site
-
Madrid, Spagna, 28040
- Research Site
-
Madrid, Spagna, 28006
- Research Site
-
Majadahonda, Spagna, 28222
- Research Site
-
Salamanca, Spagna, 37007
- Research Site
-
Seville, Spagna, 41014
- Research Site
-
Valencia, Spagna, 46014
- Research Site
-
Valencia, Spagna, 46017
- Research Site
-
Vigo, Spagna, 36200
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85028
- Research Site
-
-
California
-
Covina, California, Stati Uniti, 91722
- Research Site
-
La Jolla, California, Stati Uniti, 92037
- Research Site
-
Los Angeles, California, Stati Uniti, 90045
- Research Site
-
Los Angeles, California, Stati Uniti, 90089
- Research Site
-
Orange, California, Stati Uniti, 92868
- Research Site
-
San Francisco, California, Stati Uniti, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Stati Uniti, 33309
- Research Site
-
Miami, Florida, Stati Uniti, 33174
- Research Site
-
Plantation, Florida, Stati Uniti, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Research Site
-
Chicago, Illinois, Stati Uniti, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Research Site
-
Boston, Massachusetts, Stati Uniti, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Research Site
-
Bloomfield Hills, Michigan, Stati Uniti, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Stati Uniti, 10028
- Research Site
-
Rochester, New York, Stati Uniti, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28207
- Research Site
-
Statesville, North Carolina, Stati Uniti, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- Research Site
-
Roanoke, Virginia, Stati Uniti, 24016
- Research Site
-
-
-
-
-
Cape Town, Sud Africa, 7500
- Research Site
-
Johannesburg, Sud Africa, 2193
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10330
- Research Site
-
Bangkok, Tailandia, 10700
- Research Site
-
Hat Yai, Tailandia, 90110
- Research Site
-
Khlong Luang, Tailandia, 12120
- Research Site
-
Khon Kaen, Tailandia, 40002
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Research Site
-
Taichung, Taiwan, 404
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
-
-
-
-
Cordaleo, Turchia (Türkiye), 35575
- Research Site
-
Istanbul, Turchia (Türkiye), 34098
- Research Site
-
Kayseri, Turchia (Türkiye), 38039
- Research Site
-
Samsun, Turchia (Türkiye), 55270
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Comparatore placebo: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Lasso di tempo: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in total CLASI-A score
Lasso di tempo: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Lasso di tempo: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Lasso di tempo: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Lasso di tempo: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Lasso di tempo: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Lasso di tempo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Lasso di tempo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Lasso di tempo: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Lasso di tempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Lasso di tempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Lasso di tempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Lasso di tempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Lasso di tempo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Lasso di tempo: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Lasso di tempo: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with adverse events
Lasso di tempo: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D346BC00001
- 2021-003698-70 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .